

1、 基本資料

簽名：_____

填表日期：期：期：期：期 20 / /

::

身份證號碼	A	1	2	5	9	1	*	*	*	*
簽名：										
身份證號碼										

中文姓名	林嘉彥		英文姓名	Lin Chia-yen		
				(Last Name) (First Name) (Middle Name)		
國籍	中華民國		性別	<input checked="" type="checkbox"/> 男 <input type="checkbox"/> 女	出生日期	73 年 01 月 22 日
聯絡地址	40705 台中市西屯區台灣大道路4段1650號					
聯絡電話	(公).04-23592525#5121			(宅).0921-768087		
E-MAIL	lcyhank.tw@gmail.com					

- 2、 主要學歷 請填學士級以上之學歷或其他最高學歷均可，若仍在學者，請在學位欄填「肄業」。

畢／肄業學校	國別	主修學門系所	學位	起訖年月(西元年/月)
台北醫學大學	ROC	醫學系	學士	<u>2002 / 09</u> 至 <u>2009 / 06</u>
中山醫學大學	ROC	醫學研究所	博士	<u>2017 / 09</u> 至 <u>2020 / 06</u>

- 3、 現職及與專長相關之經歷 指與研究相關之專任職務，請依任職之時間先後順序由最近者往前追溯。

服務機關	服務部門／系所	職稱	起訖年月(西元年/月)
現職：			
台中榮民總醫院	泌尿外科	主治醫師	<u>2016 / 03</u> 起迄今
經歷：			
台中榮民總醫院	外科部/泌尿外科	住院醫師	<u>2010 / 08</u> 至 <u>2014 / 08</u>
台中榮民總醫院	外科部/泌尿外科	總醫師	<u>2014 / 08</u> 至 <u>2015 / 08</u>
台中榮民總醫院	外科部/泌尿外科	研究醫師	<u>2015 / 08</u> 至 <u>2016 / 02</u>
台中榮民總醫院	重症醫學部	主治醫師	<u>2016 / 03</u> 至 <u>2020 / 08</u>

四、專長 請自行填寫與研究方向有關之學門名稱。

泌尿腫瘤(腎臟、膀胱、攝護腺、睪丸及後腹腔)之診治、腹腔鏡微創手術、排尿障礙、攝護腺肥大、攝護腺刮除及雷射手術、泌尿系統結石、血尿、疝氣。

Research and Publications 2020-2024

1. Chang, L. W., Hung, S. C., Chen, C. S., Li, J. R., Chiu, K. Y., Wang, S. S., Yang, C. K., Lu, K., Chen, C. C., Wang, S. C., **Lin, C. Y.**, Cheng, C. L., Ou, Y. C., & Yang, S. F. Author Correction: Geriatric nutritional risk index as a prognostic marker for patients with upper tract urothelial carcinoma receiving radical nephroureterectomy. *Sci Rep.* 2024 Dec 6;14(1):30424. doi: 10.1038/s41598-024-81780-6
2. Wang, C. L., Wang, S. S., Chen, C. S., Hung, S. C., Chen, C. C., Yang, C. K., Li, J. R., Chiu, K. Y., & **Lin, C. Y.** *Enhancing screening rates for bone health management in prostate cancer patients on androgen deprivation therapy with an automated outpatient system. *Sci Rep.* 2024 Nov 18;14(1):28460. doi: 10.1038/s41598-024-79888-w.
3. Tung, M.C., **Lin, C.Y.**, Wen, Y.C., Chang, L.C., Yang, S.F., Chien, M.H. Associations of the Expression Levels and Risk Variants of CDKN2B-AS1 Long Noncoding RNA With the Susceptibility and Progression of Prostate Cancer. *J Cell Mol Med.* 2024 Dec;28(23):e70264. doi: 10.1111/jcmm.70264.
4. Weng, W.C., Hsieh, Y.H., **Lin, C.Y.**, Liu, Y.F., Su, S.C., Wang, S.S., Yang, S.F.*Functional variants of the pentraxin 3 gene are associated with the metastasis and progression of prostate cancer. *J Cell Mol Med.* 2024 Aug 26;28(16):e70041. doi: 10.1111/jcmm.70041
5. Huang, P. C., Huang, L. H., Yang, C. K., Li, J. R., Chen, C. S., Wang, S. S., Chiu, K. Y., Ou, Y. C.,* & **Lin, C. Y.** *Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective. *PLoS One.* 2024 Aug 7;19(8):e0306900. doi: 10.1371/journal.pone.0306900. eCollection 2024.
(Corresponding author)
6. **Lin, C. Y.**, Wang, C. L., Yang, C. K., Li, J. R., Chen, C. S., Chiu, K. Y., Lin, C. H., & Wang, S. S. The impact of novel hormonal agents on fracture risk in prostate cancer patients: a nationwide population-based cohort study. *Sci Rep.* 2024 Nov 4;14(1):26696. doi: 10.1038/s41598-024-73598-z.
7. Lai, G. S., Chen, C. S., Cheng, J. C., Li, J. R., Yang, C. K., **Lin, C. Y.**, Hung, S. C., Chiu, K. Y., & Wang, S. S.* Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients. *PLoS One.* 2024 Sep 6;19(9):e0309941. doi: 10.1371/journal.pone.0309941. eCollection 2024.
8. Hu, S.L., Liu, S.C., **Lin, C.Y.**, Fong, Y.C., Wang, S.S., Chen, L.C., Yang, S.F., Tang, C.H. Genetic associations of visfatin polymorphisms with clinicopathologic characteristics of prostate cancer in Taiwanese males. *Int J Med Sci.* 2024 Sep 23;21(13):2494–2501. doi: 10.7150/ijms.101020
9. Huang, H. C., Hsieh, Y. H., Hsiao, C. H., **Lin, C. Y.**, Wang, S. S., Ho, K. H., Chang, L. C., Huang, H. M., Yang, S. F., & Chien, M. H. MAOB expression correlates with a favourable prognosis in prostate cancer, and its genetic variants are associated with the metastasis of the disease. *J Cell Mol Med.* 2024 Apr;28(8):e18229. doi: 10.1111/jcmm.18229.
10. Lai, G. S., Li, J. R., Wang, S. S., Chen, C. S., Yang, C. K., **Lin, C. Y.**, Hung, S. C., Chiu, K. Y., & Yang, S. F. Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database. *PLoS One.* 2024 Mar 28;19(3):e0299102. doi: 10.1371/journal.pone.0299102. eCollection 2024.
11. Chang, L. W., Hung, S. C., Chou, Y. E., Chen, C. S., Li, J. R., **Lin, C. Y.**, Wang, S. S., & Yang, S. F. The impacts of MACC1 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan. *J Cancer.* 2023 Oct 24;14(18):3532-3538. doi: 10.7150/jca.90130.
12. Yang, H. C., Hsieh, H. C., Liao, P. C., Chang, L. W., Hu, J. C., Hung, S. C., **Lin, C. Y.**, Wang, S. C., Chen, C. C., Yang, C. K., Wang, S. S., Chen, C. S., Lu, K., Li, J. R., Cheng, C. L., & Chiu, K.

- Y. *Nephroscope-assisted single trocar peritoneal dialysis catheter insertion improves catheter survival compared with laparoscopic technique: Ten-year experience of a single-center. *Asian J Surg.* 2024 Jan;47(1):303-309. doi: 10.1016/j.asjsur.2023.08.143. Epub 2023 Sep 7.
13. Lai, G. S., Li, J. R., Wang, S. S., Chen, C. S., Yang, C. K., **Lin, C. Y.**, Hung, S. C., Chiu, K. Y., & Yang, S. F. Real world treatment sequences and outcomes for metastatic renal cell carcinoma. *PLoS One.* 2023 Nov 22;18(11):e0294039. doi: 10.1371/journal.pone.0294039. eCollection 2023.
 14. Lai, G. S., Li, J. R., Wang, S. S., Chen, C. S., Yang, C. K., **Lin, C. Y.**, Hung, S. C., Ho, H. C., Ou, Y. C., Chiu, K. Y., & Yang, S. F. Influence of Surgical Complications on Outcomes in Kidney Transplantation Patients. *In Vivo .* 2023 Nov-Dec;37(6):2796-2802. doi: 10.21873/invivo.13392.
 15. Wen, Y. C., **Lin, C. Y.**, Ho, K. H., Lin, Y. W., Hsiao, C. H., Wang, S. S., Chang, L. C., Yang, S. F., & Chien, M. H. Functional variants of the chitinase 3-like 1 gene are associated with clinicopathologic outcomes and progression of prostate cancer. *J Cell Mol Med.* 2023 Oct 30. doi: 10.1111/jcmm.18012. Online ahead of print.
 16. Wen, Y. C., **Lin, C. Y.**, Hsiao, C. H., Wang, S. S., Huang, H. C., Lin, Y. W., Ho, K. H., Chang, L. C., Yang, S. F., & Chien, M. H. Genetic variants of dipeptidyl peptidase IV are linked to the clinicopathologic development of prostate cancer. *J Cell Mol Med.* 2023 Aug 2. doi: 10.1111/jcmm.17845. Online ahead of print.
 17. **Lin, C.Y.**, Wang, C.L., Wang, S.S., Yang, C.K., Li, J.R., Chen, C.S., Hung, S.C., Chiu, K.Y., Cheng, C.L., Ou, Y.C., & Yang, S.F.* WWOX Polymorphisms as Predictors of the Biochemical Recurrence of Localized Prostate Cancer after Radical Prostatectomy. *Int J Med Sci.* 2023;20(7):969-975.doi:10.7150/ijms.84364
 18. Yang, H. C., Chang, L. W., Li, J. R., Wang, S. S., Yang, C. K., Chen, C. S., Lu, K., Chen, C. C., Wang, S. C., **Lin, C. Y.**, Cheng, C. L., Ou, Y. C., Chiu, K. Y., & Hung, S. C.*Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. *Anticancer Res.* 2023 Apr;43(4):1809-1816.
 19. Yang, C. K., Yang, C. R., Ou, Y. C., Cheng, C.L., Ho, H.C., Chiu, K.Y*., Wang, S.S., Li, J.R., Chen, C.S., Hung, C.F., Chen, C.C., Wang, S.C., **Lin, C.Y.**, & Hung, S.C. Prostate - specific antigen density and preoperative MRI findings as predictors of biochemical recurrence in high-risk and very high-risk prostate cancer. *Oncology Letters.* 2023 Jul 26;1;1792-1082. doi:10.3892/ol.2023.13870.
 20. Chang, L. W., Hung, S. C., Chen, C. S., Li, J. R., Chiu, K. Y., Wang, S. S., Yang, C. K., Lu, K., Chen, C. C., Wang, S. C., **Lin, C. Y.**, Cheng, C. L., Ou, Y. C., & Yang, S. F. Geriatric nutritional risk index as a prognostic marker for patients with upper tract urothelial carcinoma receiving radical nephroureterectomy. *Sci Rep .* 2023 Mar; 13(1):4554.
 21. Hsieh, H. C., Wang, C. L., Chen, C. S., Yang, C. K., Li, J. R., Wang, S. S., Cheng, C. L., **Lin, C. Y.**,* & Chiu, K. Y.* The prognostic impact of lymph node dissection for clinically node-negative upper urinary tract urothelial carcinoma in patients who are treated with radical nephroureterectomy. *PLoS One.* 2022 Dec;17(12):e0278038. (IF=3.7 R/C=26/73 36%, MULTIDISCIPLINARY SCIENCES)
 22. Hsieh, C. Y., **Lin, C. Y.**, (co-first author)Wang, S. S., Chou, Y. E., Chien, M. H., Wen, Y. C., Hsieh, M. J., & Yang, S. F. Impact of Clinicopathological Characteristics and Tissue Inhibitor of Metalloproteinase-3 Polymorphism Rs9619311 on Biochemical Recurrence in Taiwanese Patients with Prostate Cancer. *Int J Environ Res Public Health.*2023 Dec; 20(1):306. <https://doi.org/10.3390/ijerph20010306> 非SCI文章

23. Wang, C. L., **Lin, C. Y.,*** & Yang, S. F.* Hospice Care Improves Patients' Self-Decision Making and Reduces Aggressiveness of End-of-Life Care for Advanced Cancer Patients. *Int J Environ Res Public Health*. 2022 Nov 24;19(23):15593. doi: 10.3390/ijerph192315593. 非SCI文章
24. Chou, Y. E., Hsieh, M. J., Wang, S. S., **Lin, C. Y.**, Chen, Y. Y., Ho, Y. C., & Yang, S. F. The impact of receptor of advanced glycation end-products polymorphisms on prostate cancer progression and clinicopathological characteristics. *J Cell Mol Med*. 2021 Nov; 25(22): 10761–10769. Published online 2021 Oct 27. doi: 10.1111/jcmm.17025
25. Chen, C. S., Li, J. R., Yang, C. K., Cheng, C. L., Yang, C. R., Ou, Y. C., Ho, H. C., **Lin, C. Y.**, Hung, S. C., Chen, C. C., Wang, S. C., & Wang, S. S. Significant predictors of contralateral upper tract recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. *Int J Urol*. 2021 Oct; 29(1): 69-75.
26. Hung, S. C., Chang, L. W., Li, J. R., Wang, S. S., Yang, C. K., Chen, C. S., Lu, K., Chen, C. C., Wang, S. C., **Lin, C. Y.**, Cheng, C. L., Ou, Y. C., Chiu, K. Y. * Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. *In Vivo*. 2021 Nov-Dec;35(6):3509-3519.
27. Hu, J. C., Wang, S. S., Chou, Y. E., Chiu, K. Y., Li, J. R., Chen, C. S., Hung, S. C., Yang, C. K., Ou, Y. C., Cheng, C. L., **Lin, C. Y.,*** Yang, S. F. * Associations between lncRNA MALAT1 Polymorphisms and Lymph Node Metastasis in Prostate Cancer. *Diagnostics (Basel)*, 2021 Sep 16;11(9):1692. doi: 10.3390/diagnostics11091692.
28. Wang, C. L., Hsu, P. S., **Lin, C. Y.***, & Yang, S. F.*. Clinical Factors Associated with Asymptomatic Women Having Inconclusive Screening Mammography Results: Experiences from a Single Medical Center in Taiwan. *Int J Environ Res Public Health*. 2021 May; 18(10): 5410. doi:10.3390/ijerph18105410 非SCI文章
29. Chen, C. S., **Lin, C. Y. (co-first author)**, Wang, C. L., Wang, S. S., Li, J. R., Yang, C. K., . . . Yang, S. F.* Association between lymphovascular invasion and oncological outcome in node-negative upper tract urothelial carcinoma with different stage. *Urol Oncol*. 2021 Feb;39(2):132.e13-132.e26. Epub 2020 Sep 6.
30. Chang LW, Hung SC, Li JR, Chiu KY, Yang CK, Chen CS, Lu K, Chen CC, Wang SC, **Lin CY**, Cheng CL, Ou YC, Yang SF, Hsu CY, Ho SH, Wang SS. * Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel. *Front Pharmacol*. 2021 Jan 25;11:601513. doi: 10.3389/fphar.2020.601513. eCollection 2020.
31. Chou, Y. E., Yang, P. J., **Lin, C. Y.**, Chen, Y. Y., Chiang, W. L., Lin, P. X., Huang, Z. Y., Huang, M., Ho, Y. C., & Yang, S. F. The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics. *Int J Environ Res Public Health*. 2020 Oct; 17(19): 7247. Published online 2020 Oct 3. doi: 10.3390/ijerph17197247 非SCI文章
32. Li, C. C., Hsieh, M. J., Wang, S. S., Hung, S. C., **Lin, C. Y.**, Kuo, C. W., . . . Chou, Y. E. Impact of Matrix Metalloproteinases 11 Gene Variants on Urothelial Cell Carcinoma Development and Clinical Characteristics. *Int J Environ Res Public Health*. 2020 Jan 11;17(2):475. doi: 10.3390/ijerph17020475. 非SCI文章
33. Hung, S. C., Chou, Y. E., Li, J. R., Chen, C. S., **Lin, C. Y.**, Chang, L. W., Chiu, K. Y., Cheng, C. L., Ou, Y. C., Wang, S. S., * Yang, S. F.* Functional genetic variant of WW domain containing oxidoreductase gene associated with urothelial cell carcinoma clinicopathologic characteristics and long-term survival. *Urol Oncol*. 2020 Feb;38(2):41.e1-41.e9. doi: 10.1016/j.urolonc.2019.07.016. Epub 2019 Aug 29.
34. Chen, C. S., Li, J. R., Wang, S. S., Yang, C. K., Cheng, C. L., Yang, C. R., Ou, Y. C., Ho, H. C.,

- Lin, C. Y.**, Hung, S. C., Chen, C. C., Wang, S. C., Chiu, K. Y.* and Yang, S. F.* Tumor Multifocality is a Significant Risk Factor of Urinary Bladder Recurrence after Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma: A Single-Institutional Study. *Diagnostics (Basel)*. 2020 Apr 3;10(4):201. doi: 10.3390/diagnostics10040201.
35. Hu, J. C., **Lin, C. Y.**, Wang, S. S., Chiu, K. Y., Li, J. R., Chen, C. S., . . . Yang, S. F.* Impact of H19 Polymorphisms on Prostate Cancer Clinicopathologic Characteristics. *Diagnostics (Basel)*. 2020 Aug 31;10(9):656. doi: 10.3390/diagnostics10090656.
36. Hsieh, C. Y., Chou, Y. E., **Lin, C. Y.**, Wang, S. S., Chien, M. H., Tang, C. H., . . . Yang, S. F.* Impact of Matrix Metalloproteinase-11 Gene Polymorphisms on Biochemical Recurrence and Clinicopathological Characteristics of Prostate Cancer. *Int J Environ Res Public Health*, 2020 Nov 19;17(22):8603. doi: 10.3390/ijerph17228603. 非SCI文章